| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2009 | WO2009026241A1 Heterocyclic modulators of tgr5 |
| 02/26/2009 | WO2009026239A1 Small molecule inhibitors of lck sh2 domain binding |
| 02/26/2009 | WO2009026234A1 Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| 02/26/2009 | WO2009026227A2 Highly selective sigma receptor ligands |
| 02/26/2009 | WO2009026204A1 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| 02/26/2009 | WO2009026197A1 Novel cathepsin c inhibitors and their use |
| 02/26/2009 | WO2009026191A1 Alpha-pentafluorosufanyl aldehydes, ketones and acids |
| 02/26/2009 | WO2009026179A2 Antiinfective proanthocyanidin compounds and methods of use thereof |
| 02/26/2009 | WO2009026178A2 High concentration local anesthetic formulations |
| 02/26/2009 | WO2009026176A2 Antiinfective flavononol compounds and methods of use thereof |
| 02/26/2009 | WO2009026169A2 Oncotherapeutic application of inhibitors of high-affinity glucose transporters |
| 02/26/2009 | WO2009026166A2 Antiinfective flavonol compounds and methods of use thereof |
| 02/26/2009 | WO2009026163A1 Compositions and methods for inhibiting growth and metastasis of melanoma |
| 02/26/2009 | WO2009026135A2 Controlled transdermal bisoprolol delivery system |
| 02/26/2009 | WO2009026133A2 Transdermal bisoprolol delivery system |
| 02/26/2009 | WO2009026107A1 Protein kinase inhibitors |
| 02/26/2009 | WO2009026083A1 ζA MEMORY INFLUENCING PROTEIN |
| 02/26/2009 | WO2009026009A1 Compositions and methods for modulating endophthalmitis using fluoroquinolones |
| 02/26/2009 | WO2009025914A2 Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging |
| 02/26/2009 | WO2009025876A2 Crystalline forms of erlotinib hcl and formulations thereof |
| 02/26/2009 | WO2009025875A1 Stable formulations of crystalline erlotinib hcl |
| 02/26/2009 | WO2009025839A2 Phosphodiesterase 10 inhibitors |
| 02/26/2009 | WO2009025830A1 Treatment of lung cancer |
| 02/26/2009 | WO2009025823A1 Phosphodiesterase 10 inhibitors |
| 02/26/2009 | WO2009025820A2 Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution |
| 02/26/2009 | WO2009025792A2 Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| 02/26/2009 | WO2009025791A2 Purification of armodafinil |
| 02/26/2009 | WO2009025785A2 Cb2 receptor ligands for the treatment of pain |
| 02/26/2009 | WO2009025784A1 Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/26/2009 | WO2009025751A1 Pyridazine based alpha-helix mimetics |
| 02/26/2009 | WO2009025733A1 Antifungal agents |
| 02/26/2009 | WO2009025699A1 Topical medication garment and system and method for providing topical medication |
| 02/26/2009 | WO2009025618A1 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy |
| 02/26/2009 | WO2009025617A1 Combinations containing mpo inhibitors against neuroinflammatory disorders |
| 02/26/2009 | WO2009025576A1 Method for producing the micronised powder of encapsulated organic medicinal substance having a slow water solubility |
| 02/26/2009 | WO2009025571A1 Sublingual or buccal pharmaceutical compositions comprising succinic acid for treating alzheimer's disease |
| 02/26/2009 | WO2009025477A1 Indole compounds as an inhibitor of cellular necrosis |
| 02/26/2009 | WO2009025372A1 Composition containing reduced coenzyme q10, and method for stabilizing the composition |
| 02/26/2009 | WO2009025358A1 Heterocyclic compound and use thereof |
| 02/26/2009 | WO2009025328A1 Ascorbic acid derivative or salt thereof, method for producing the same, and cosmetic preparation |
| 02/26/2009 | WO2009025326A1 Method for production of hydroxytyrosol-containing aqueous olive extract |
| 02/26/2009 | WO2009025315A1 Oral preparation for improvement of bioavailability of curcumin |
| 02/26/2009 | WO2009025277A1 Method of producing reduced coenzyme q10 and method of stabilizing the same |
| 02/26/2009 | WO2009025265A1 Piperazine derivative |
| 02/26/2009 | WO2009025239A1 Novel preparation for external use |
| 02/26/2009 | WO2009025159A1 Detection and treatment of schizophrenia |
| 02/26/2009 | WO2009025116A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009025091A1 Pharmaceutical composition for treatment of fibromyalgia |
| 02/26/2009 | WO2009025062A1 External preparation for skin |
| 02/26/2009 | WO2009024998A1 Nitric oxide releasing derivatives of paracetamol |
| 02/26/2009 | WO2009024997A1 Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer |
| 02/26/2009 | WO2009024989A2 A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| 02/26/2009 | WO2009024980A2 Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors |
| 02/26/2009 | WO2009024924A1 Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin |
| 02/26/2009 | WO2009024906A1 4-pyrimidinesulfamide derivative |
| 02/26/2009 | WO2009024905A1 Pyridine derivatives as s1p1/edg1 receptor modulators |
| 02/26/2009 | WO2009024858A1 Controlled release dosage form of galantamine |
| 02/26/2009 | WO2009024825A1 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| 02/26/2009 | WO2009024824A1 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| 02/26/2009 | WO2009024821A2 Oxadiazole derivatives as dgat inhibitors |
| 02/26/2009 | WO2009024820A2 Therapeutic treatment 014 |
| 02/26/2009 | WO2009024763A2 Combination therapy |
| 02/26/2009 | WO2009024707A2 Use of radamea montana extract for preparing a cosmetic composition |
| 02/26/2009 | WO2009024686A2 Novel method for producing dry hydrodispersible pharmaceutical forms |
| 02/26/2009 | WO2009024680A1 Use of oleocanthal for treatment of cutaneous inflammation |
| 02/26/2009 | WO2009024677A2 Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection |
| 02/26/2009 | WO2009024670A2 Hyaluronic acid injectable gel for treating joint degeneration |
| 02/26/2009 | WO2009024667A2 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 02/26/2009 | WO2009024615A1 Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| 02/26/2009 | WO2009024613A1 Tetracyclic indolopyridines as eg5 inhibitors |
| 02/26/2009 | WO2009024611A2 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
| 02/26/2009 | WO2009024590A2 Antifungal composition |
| 02/26/2009 | WO2009024585A2 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
| 02/26/2009 | WO2009024550A1 N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators |
| 02/26/2009 | WO2009024543A1 Use of tranilast and derivatives thereof for the therapy of neurological conditions |
| 02/26/2009 | WO2009024542A2 Purin derivatives for use in the treatment of fab-related diseases |
| 02/26/2009 | WO2009024541A2 Isoxazoline compositions and their use as antiparasitics |
| 02/26/2009 | WO2009024535A1 Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
| 02/26/2009 | WO2009024517A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands |
| 02/26/2009 | WO2009024516A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands |
| 02/26/2009 | WO2009024515A1 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands |
| 02/26/2009 | WO2009024502A1 Pyrrolidine aryl-ether as nk3 receptor antagonists |
| 02/26/2009 | WO2009024491A1 Use of mglur5 antagonists for the treatment of gerd |
| 02/26/2009 | WO2009024429A2 Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| 02/26/2009 | WO2009024361A1 Hair treatment compositions with alcohol(s) and melatonin/agomelatine |
| 02/26/2009 | WO2009024360A1 Hair treatment compositions with surfactant(s) and melatonin/agomelatin |
| 02/26/2009 | WO2009024359A1 Hair treatment agent with conditioner(s) and melatonin/agomelatin |
| 02/26/2009 | WO2009024348A1 Method for activating regulatory t-cells |
| 02/26/2009 | WO2009024332A1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 02/26/2009 | WO2009024325A2 Treatment of sleep disorders |
| 02/26/2009 | WO2009024287A2 Azoloraine derivatives, method for the production thereof, pharmaceuticals containing these compounds, and the use thereof |
| 02/26/2009 | WO2009024221A1 6-thioxo-pyridazine derivatives |
| 02/26/2009 | WO2009024190A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| 02/26/2009 | WO2009024095A1 Method of making and administering quinoline derivatives as anti-cancer agents |
| 02/26/2009 | WO2009024026A1 Gastrodia elata polysaccharide, its sulfated derivative and their preparation and use |
| 02/26/2009 | WO2009024022A1 Fatty acid bile acid conjugates and medical uses thereof |
| 02/26/2009 | WO2009024016A1 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl -propyl)-6,7-dihydro -1h- pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors |
| 02/26/2009 | WO2009023978A1 Pyrazolo [3,4 -d] pyrimidine compounds and their use as modulators of protein kinase |
| 02/26/2009 | WO2009023964A1 Renin inhibitors |
| 02/26/2009 | WO2009023961A1 Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |